Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
A legfontosabb adatok
- Ki végzi
- Sanofi
- Hol
- Buffalo és El Paso (Egyesült Államok)Mind a 2 helyszín megnézéseMég 6 másik országban, 33 helyszínen
- Azonosító
- NCT05245071
- EudraCT 2021-004423-32
- U1111-1264-2828
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 22 fő vett részt
- Kezdés
- 2022. jún. 1.
- Befejezés
- 2024. nov. 20.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Tusamitamab ravtansine
- A regiszteradat frissítve
- 2025. augusztus 29.
- Miért állt le
- Sponsor decision, the decision is not related to any safety concern.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Histologically or cytologically proven diagnosis of NSQ NSCLC metastatic disease at study entry; progression after platinum-based chemotherapy and immune checkpoint inhibitor
- Participants with moderate or negative CEACAM5 expression as demonstrated prospectively by central laboratory via immune histochemistry (ICH) and high circulating CEA levels (≥100 ng/mL). Moderate CEACAM5 expression is defined as intensity ≥ 2 + in ≥ 1% and <50 % of tumor cells. Negative CEACAM5 expression is defined as intensity of 1 + whatever the percentage of stained tumor cells or <1% of tumor cells
- At least one measurable lesion by RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Women of childbearing potential or male patient with women of childbearing potential who agree to use highly effective method of birth control
Ki nem vehet részt
- Significant concomitant illness that could impair the participation in the study or interpretation of the results or any major surgery with 3 weeks prior treatment administration
- Nonresolution of any prior treatment-related toxicity to <Grade 2 according to NCI CTCAE v5.0, with the exception of alopecia, vitiligo, or active thyroiditis controlled with hormone replacement therapy
- Previous history of and/or unresolved corneal disorders. The use of contact lenses is not permitted
- Prior treatment with maytansinoid derivatives (DM1 or DM4 antibody drug conjugate) or any drug targeting CEACAM5
- Concurrent treatment with any other anticancer therapy
- Patients with untreated brain metastases or history of leptomeningeal disease
- History within the last 3 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment
- History of known uncontrolled infection with human immunodeficiency virus (HIV), or unresolved viral hepatitis
- Poor bone marrow, liver or kidney functions; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Helyszínek itt: Egyesült Államok
Még 6 másik országban, 33 helyszínen
- Roswell Park Cancer Institute Site Number : 8400004Buffalo, Egyesült Államok
- El Paso, TexasHospital not named in the registry
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is an open label single group, Phase 2, 1-arm study for treatment to evaluate efficacy, safety, and Pharmacokinetic (PK) of tusamitamab ravtansine in nonsquamous non-small-cell-lung-cancer (NSQ NSCLC) participants with negative or moderate CEACAM5 expression tumors and high circulating carcinoembryonic antigen (CEA).
A teljes eredeti leírásKevesebb
Participants who will be enrolled, will receive tusamitamab ravtansine as monotherapy every two weeks (Q2W) until disease progression, unacceptable adverse event (AE), initiation of a new anticancer therapy, or the participant's or investigator's decision to stop the treatment, whichever comes first. A total of approximately 38 participants are planned to be treated.
A vizsgálat csoportja
- Tusamitamab ravtansineA vizsgált kezelés
Tusamitamab ravtansine dose will be administered on Day 1 via IV infusion and repeated once every 2 weeks. The duration of 1 cycle will be 14 days (1 administration of tusamitamab ravtansine per cycle).
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
- A regiszteradat frissítve
- 2025. augusztus 29.